ES2673406T3 - Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos en el tratamiento de la diabetes - Google Patents

Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos en el tratamiento de la diabetes Download PDF

Info

Publication number
ES2673406T3
ES2673406T3 ES14195394.3T ES14195394T ES2673406T3 ES 2673406 T3 ES2673406 T3 ES 2673406T3 ES 14195394 T ES14195394 T ES 14195394T ES 2673406 T3 ES2673406 T3 ES 2673406T3
Authority
ES
Spain
Prior art keywords
cis
acid
octadecenoic acid
hydroxy
octadecenoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14195394.3T
Other languages
English (en)
Inventor
Pablo Vicente ESCRIBÁ RUIZ
Xavier Busquets Xaubet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of the Balearic Islands
Original Assignee
University of the Balearic Islands
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42242375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2673406(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of the Balearic Islands filed Critical University of the Balearic Islands
Application granted granted Critical
Publication of ES2673406T3 publication Critical patent/ES2673406T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Compuesto seleccionado entre: ácido α-hidroxi-cis-Δ9-hexadecenoico (OHHD), ácido α-hidroxi-cis-Δ9-octadecenoico (OHOD), ácido α-metil-cis-Δ9-octadecenoico (MOD), ácido α-amino-cis-Δ9-octadecenoico (AOD), ácido α-fluoro-cis-Δ9-octadecenoico (FOD), ácido α-trifluorometil-cis-Δ9-octadecenoico (TFMOD), ácido α-metoxi-cis-Δ9-octadecenoico (MOOD), ácido α-mercapto-cis-Δ9-octadecenoico (SHOD), ácido α-metil-cis-Δ11-octadecenoico (MOD11), ácido α-hidroxi-cis-Δ11-octadecenoico (OHOD11), ácido α-hidroxi-cis-Δ11-eicosenoico (OHEE), ácido α-hidroxi-cis-Δ13- docosenoico (OHDE), sal sódica del ácido α-hidroxi-cis--Δ9-octadecenoico (Na-OHOD), α-hidroxi-cis-Δ9-octadecenoato de metilo (OMe-OHOD), α-hidroxi-cis-Δ9-octadecenoato de etilo (EE-OHOD), sal amónica del ácido α-hidroxi-cis-Δ9-octadecenoico (NH3-OHOD), ácido α-acetil-cis-Δ9-octadecenoico (ACOD), sal sódica del ácido α-acetil-cis-Δ9-octadecenoico (Na-ACOD), α-acetil-cis-Δ9-octadecenoato de metilo (OMe-ACOD), α-acetil-cis-Δ9-octadecenoato de etilo (EE-ACOD), sal sódica del ácido α-metoxi-cis-Δ9-octadecenoico (Na-MOOD), α-metoxi- cis-Δ9-octadecenoato de metilo (OMe-MOOD), α-metoxi- cis-Δ9-octadecenoato de etilo (EE-MOOD), ácido α-dietil-fosfatidil-cis-Δ9-octadecenoico (DEPOD), sal sódica del ácido α-dietil-fosfatidil-cis-Δ9-octadecenoico (Na-DEPOD), α-dietil-fosfatidil-cis-Δ9-octadecenoato de metilo (OMe-DEPOD) o α-dietil-fosfatidil-cis-Δ9-octadecenoato de etilo (EE-DEPOD), para uso, independientemente o en combinación con al menos otro compuesto, como medicamento o nutracéutico, en el tratamiento de la diabetes.
ES14195394.3T 2008-12-09 2009-12-04 Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos en el tratamiento de la diabetes Active ES2673406T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200803480A ES2342997B1 (es) 2008-12-09 2008-12-09 Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ES200803480 2008-12-09

Publications (1)

Publication Number Publication Date
ES2673406T3 true ES2673406T3 (es) 2018-06-21

Family

ID=42242375

Family Applications (5)

Application Number Title Priority Date Filing Date
ES200803480A Active ES2342997B1 (es) 2008-12-09 2008-12-09 Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ES09831504.7T Active ES2535498T3 (es) 2008-12-09 2009-12-04 Alfa derivados de ácidos grasos cis-monoinsaturados para ser usados como medicamento
ES18164265T Active ES2899274T3 (es) 2008-12-09 2009-12-04 Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos
ES14195436.2T Active ES2661412T3 (es) 2008-12-09 2009-12-04 Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos
ES14195394.3T Active ES2673406T3 (es) 2008-12-09 2009-12-04 Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos en el tratamiento de la diabetes

Family Applications Before (4)

Application Number Title Priority Date Filing Date
ES200803480A Active ES2342997B1 (es) 2008-12-09 2008-12-09 Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ES09831504.7T Active ES2535498T3 (es) 2008-12-09 2009-12-04 Alfa derivados de ácidos grasos cis-monoinsaturados para ser usados como medicamento
ES18164265T Active ES2899274T3 (es) 2008-12-09 2009-12-04 Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos
ES14195436.2T Active ES2661412T3 (es) 2008-12-09 2009-12-04 Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos

Country Status (18)

Country Link
US (3) US9000042B2 (es)
EP (4) EP2842556B1 (es)
JP (2) JP5711140B2 (es)
KR (1) KR101683643B1 (es)
CN (1) CN102355897B (es)
AU (6) AU2009326993B2 (es)
BR (1) BRPI0922870A8 (es)
CA (1) CA2745052C (es)
DK (3) DK2842556T3 (es)
ES (5) ES2342997B1 (es)
HU (2) HUE056170T2 (es)
IL (1) IL213354A (es)
MX (1) MX2011005978A (es)
PL (3) PL3366285T3 (es)
PT (4) PT2842556T (es)
RU (1) RU2531353C2 (es)
SI (1) SI3366285T1 (es)
WO (1) WO2010066931A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342997B1 (es) 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
WO2011089265A1 (en) * 2010-01-25 2011-07-28 Bridge Bioresearch Plc Use of fatty acid compounds for lowering blood glucose levels
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO2013132092A1 (en) 2012-03-09 2013-09-12 Pensieve International Plc Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat
JP6348229B2 (ja) * 2014-10-21 2018-06-27 ユニバーシタット デ レス イレス バレアレス ヒドロキシ−トリグリセリドの合成方法、および疾患の予防および処置のためのその使用
CA3082144A1 (en) * 2017-11-16 2019-05-23 The Research Foundation For The State University Of New York Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies
IL295120A (en) * 2020-01-29 2022-09-01 Univ Illes Balears alpha-hydroxylated fatty-acid metabolites, their medical uses and their use as biomarkers
ES2911474B2 (es) * 2020-11-17 2023-02-06 Univ Illes Balears Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
US12440467B2 (en) * 2021-12-09 2025-10-14 The Florida International University Board Of Trustees Treatment and prevention of infections using vegetable oil-derived polyols
ES2982396A1 (es) * 2023-03-14 2024-10-15 Veritas Therapeutics S L 2-hidroxi-octadecen-9-cis-oato para uso en el tratamiento de patologias oncologicas y del dolor neuropatico

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4928172B1 (es) * 1969-10-27 1974-07-24
CH558321A (de) * 1971-08-03 1975-01-31 Ciba Geigy Ag Verfahren zur herstellung von carbonsaeuren bezw. carbonsaeuresalzen.
US3931306A (en) 1973-10-23 1976-01-06 International Flavors & Fragrances Inc. Process for producing isomer mixtures containing high proportions of cis-2-methyl-3-pentenoic acid
DE2448339A1 (de) * 1974-10-10 1976-04-22 Basf Ag Verfahren zur herstellung von olefinisch ungesaettigten carbonsaeureestern
DE2559201B2 (de) * 1975-12-30 1978-06-15 Hoechst Ag, 6000 Frankfurt Organozinnverbindungen und ihre Verwendung als Stabilisatoren
US4241097A (en) * 1979-09-13 1980-12-23 International Flavors & Fragrances Inc. Use of benzodionones in augmenting or enhancing the aroma and taste of a foodstuff
US4391757A (en) * 1981-11-27 1983-07-05 Carstab Corporation Organic antimony containing stabilizer compositions for halogenated polymers
JPS5899432A (ja) * 1981-12-09 1983-06-13 Maruzen Sekiyu Kagaku Kk 不飽和脂肪酸またはその塩およびそれからなる抗菌剤
US4551279A (en) * 1984-01-09 1985-11-05 G. D. Searle & Co. Protease inhibitors
FR2609032B1 (fr) * 1986-12-30 1990-01-05 Centre Nat Rech Scient Epoxydes fonctionnels enantiomeriquement purs, leur procede de preparation et leur application comme synthons chiraux
US4808403A (en) * 1987-03-17 1989-02-28 International Flavors & Fragrances Inc. Use of N,N-diethyl-m-toluamide and/or the ethyl ester of 2-methyl-3-pentenoic acid as insect attractants
US5504107A (en) * 1990-01-12 1996-04-02 The Ohio State University Research Foundation Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids and pharmaceutical use thereof
GB9003201D0 (en) * 1990-02-13 1990-04-11 Unilever Plc Cosmetic composition
US5208260A (en) * 1990-03-29 1993-05-04 G. D. Searle & Co. Vinyl Glycine derivatives for memory and learning enhancement or treatment of a cognitive disorder
US5198250A (en) 1990-07-16 1993-03-30 Lipotech Partners Limited Partnership Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using
WO1992018116A1 (en) * 1991-04-10 1992-10-29 Yu Ruey J Compositions comprising 2-hydroxycarboxylic acids and related compounds, and methods for alleviating signs of dermatological aging
US6300373B1 (en) 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
JP3489703B2 (ja) * 1995-10-23 2004-01-26 株式会社ノエビア 微細エマルション組成物
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
JPH10182338A (ja) * 1996-12-20 1998-07-07 Noevir Co Ltd 水中油型乳化組成物
AU740588B2 (en) * 1997-11-24 2001-11-08 Scripps Research Institute, The Inhibitors of gap junction communication
GB9926833D0 (en) * 1999-11-15 2000-01-12 Univ Sunderland Compositions
GB2385589A (en) * 2000-08-07 2003-08-27 Sofitech Nv Surfactant
ES2186576B1 (es) 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
US6702756B2 (en) * 2001-12-11 2004-03-09 University Technologies International Inc. Method and apparatus for diagnosing neurological impairment
RU2004125878A (ru) 2002-01-22 2005-05-27 Зингента Партисипейшнс Аг (Ch) Фенилзамещенные гетероциклические соединения, пригодные для применения в качестве гербицидов
US7462349B2 (en) * 2002-10-24 2008-12-09 Nurit Kalderon Beta interferon for the treatment of chronic spinal cord injury
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN102210852B (zh) * 2003-05-15 2016-10-19 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
KR100756890B1 (ko) * 2005-08-19 2007-09-07 경희대학교 산학협력단 신경세포 보호활성을 갖는 올레산을 함유하는 조성물
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
WO2009127009A1 (en) 2008-04-18 2009-10-22 Commonwealth Scientific And Industrial Research Organisation Condensation polymers
EP2265654A1 (en) * 2008-04-18 2010-12-29 Commonwealth Scientific and Industrial Research Organisation Polyurethanes
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.

Also Published As

Publication number Publication date
EP3366285B1 (en) 2021-06-30
KR20110126100A (ko) 2011-11-22
AU2016228171A1 (en) 2016-09-29
EP3366285A1 (en) 2018-08-29
IL213354A0 (en) 2011-07-31
EP2374453A1 (en) 2011-10-12
CA2745052A1 (en) 2010-06-17
EP2374453B1 (en) 2015-02-18
AU2009326993B2 (en) 2016-06-16
DK3366285T3 (da) 2021-10-04
ES2661412T3 (es) 2018-03-28
US10588883B2 (en) 2020-03-17
ES2342997A1 (es) 2010-07-20
EP2842555A2 (en) 2015-03-04
AU2018229472A1 (en) 2018-10-04
AU2016228167A1 (en) 2016-09-29
RU2011128335A (ru) 2013-01-20
DK2374453T3 (en) 2015-03-30
JP5711140B2 (ja) 2015-04-30
DK2842556T3 (en) 2018-03-26
WO2010066931A1 (es) 2010-06-17
AU2019222955B2 (en) 2020-11-05
EP2842556B1 (en) 2018-01-31
EP2842556A2 (en) 2015-03-04
AU2019222955A1 (en) 2019-09-19
PT2374453E (pt) 2015-04-28
PT2842556T (pt) 2018-03-19
KR101683643B1 (ko) 2016-12-07
HUE056170T2 (hu) 2022-01-28
ES2535498T8 (es) 2016-08-19
PL3366285T3 (pl) 2022-01-10
CN102355897B (zh) 2014-06-04
EP2842556A3 (en) 2015-08-05
US9000042B2 (en) 2015-04-07
EP2374453A4 (en) 2012-05-30
ES2899274T3 (es) 2022-03-10
BRPI0922870A8 (pt) 2017-12-26
AU2018229472B2 (en) 2019-07-18
AU2018229474B2 (en) 2019-08-22
SI3366285T1 (sl) 2021-11-30
US20180193297A1 (en) 2018-07-12
PL2374453T3 (pl) 2015-07-31
MX2011005978A (es) 2011-10-11
EP2842555A3 (en) 2015-04-15
AU2018229474A1 (en) 2018-10-04
PL2842556T3 (pl) 2018-07-31
ES2535498T3 (es) 2015-05-12
JP2015061856A (ja) 2015-04-02
US20150297548A1 (en) 2015-10-22
US9730906B2 (en) 2017-08-15
IL213354A (en) 2017-06-29
ES2342997B1 (es) 2011-06-06
AU2009326993A1 (en) 2011-07-07
RU2531353C2 (ru) 2014-10-20
PT2842555T (pt) 2018-07-06
CN102355897A (zh) 2012-02-15
US20110294883A1 (en) 2011-12-01
JP2012511510A (ja) 2012-05-24
EP2842555B1 (en) 2018-04-18
CA2745052C (en) 2017-11-07
WO2010066931A4 (es) 2010-08-05
BRPI0922870A2 (pt) 2016-01-12
PT3366285T (pt) 2021-10-07
HUE037396T2 (hu) 2018-08-28

Similar Documents

Publication Publication Date Title
CY1120389T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη και μεθειονινη
NI201200013A (es) Composición de insulina de acción prolongada
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
RU2009118942A (ru) Способ стимуляции регенерации тканей
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
CO6351742A2 (es) Compuestos organicos para la cicatrizacion de heridas
CL2009001340A1 (es) Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto.
BR112013000537A2 (pt) composição aquosa contendo bromexina
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
UY31873A (es) Pirrolidin sulfonamidas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparación y su uso como sustancias farmacéuticas
CL2013000716A1 (es) Un profarmaco o una sal del mismo que comprende un conjugado de exendina-conector; procedimiento de preparacion de dicho profarmaco; compuestos intermediarios; composicion farmaceutica que lo comprende, util para mejorar el control glucemico en pacientes con diabetes de tipo 2.
CL2010000935A1 (es) Compuestos derivados de niacina unida a un acido graso; composicion farmaceutica que los comprende; y su uso para tratar una enfermedad metabolica tal como hipertrigliceridemia, hipercolesterolemia, diabetes tipo 2 y retinopatia diabetica.
AR080884A1 (es) Conjugados de insulina-sirna
UY31872A (es) Sulfonamidas n-heterocíclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparación y su uso como sustancias farmacéuticas
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
MX2014006574A (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
BR112013024973A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2
MX2011011858A (es) Composiciones borinicas.
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
AR086395A1 (es) Envase para el tratamiento de patologias
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
BR112013018738A2 (pt) novos derivados de tetrahidroquinolina
UY31874A (es) Sulfonamidas con grupo de cabeza de heterociclo y oxadiazolona, procesos para su preparación y su uso como sustancias farmacéuticas
GT200600463A (es) Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas
UY33453A (es) Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina